Showing 130 results
October 2017
-
Media Release
Novartis partners with medical experts, patient group to raise awareness on psoriasis
In observance of World Psoriasis Day on October 29, 2017 Novartis Healthcare Philippines in partnership with the Philippine Dermatological Society (PDS), Philippine Rheumatology Association (PRA),… -
Media Release
Novartis, Philippine College of Chest Physicians launch COPD awareness campaign
Chronic Obstructive Pulmonary Disease (COPD), the seventh leading cause of death in the Philippines, has a destructive impact on patients’ function and quality of life, and increases the risk of…
July 2017
-
Media Release
Novartis partners with local diabetes experts to enhance primary care physicians’ skills in diabetes diagnosis and management
Type 2 diabetes mellitus (T2DM) is one of the leading causes of sickness and death in the Philippines. To help address this problem, Novartis Healthcare Philippines, the American Association of… -
Media Release
DOH, Novartis gather stakeholders to achieve zero leprosy transmission in PH
The Stakeholders Meeting on Leprosy aims to galvanize efforts to achieve zero transmission of leprosy in the Philippines. It was held on July 5-6, 2017 at the Manila Diamond Hotel, with the theme “…
June 2017
-
Media Release
Increased awareness on organ donation key to saving lives of Filipinos requiring kidney transplantation
For many patients with end-stage renal disease (ESRD), the only option for survival is a kidney transplant. Unfortunately in the Philippines, the number of living and deceased kidney donors… -
Media Release
Novartis’ secukinumab shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years
Secukinumab is the first and only IL-17A inhibitor to show sustained improvements in signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) Additional data show rapid and…
March 2017
-
Featured News
Novartis gathers local experts, Filipino mothers to highlight women’s journey in ADHD, Alzheimer’s disease and epilepsy
-
Media Release
Novartis’ secukinumab is first and only IL-17A inhibitor to potentially modify the course of psoriasis
New data suggests that disease modification with secukinumab may be achievable for around 20% of patients following one year of treatment1 Patients with longer disease duration before treatment… -
Media Release
Novartis partners with ADB, Swiss Embassy to hold forum on achieving universal health coverage in developing countries
Swiss and Filipino stakeholders in the healthcare sector gather at the Asian Development Bank (ADB) headquarters in Mandaluyong City to present and learn from innovative health policies and… -
Media Release
Novartis global survey shows 85% fear blindness, but only 33% have regular eye examination
Survey shows 85% of respondents are most afraid to lose eye sight of their five senses, 87% of respondents believe regular eye exams are important but only 33% reported visiting annual screenings…